Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.

Antiviral chemistry & chemotherapy - 1 Jan 2007

Borroto-Esoda Katyna, Parkin Neil, Miller Michael D

Abstract excerpt

Emtricitabine (FTC) and lamivudine (3TC) are cytosine nucleoside analogues approved for use in HIV-1 infection. Both compounds select for the M184V/I mutation resulting in high-level resistance. This study compared the phenotypic resistance profiles of FTC and 3TC. Both compounds were tested against clinical samples submitted for routine resistance testing (PhenoSense HIV assay). We evaluated 306 viruses with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Deoxycytidine
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Emtricitabine

Share to HIV Reverse Transcriptase

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 18046962
DOI: 10.1177/095632020701800505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.PMID 18046962Read ↗

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.Semantic proximity Read ↗

A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.Semantic proximity Read ↗

Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs.Semantic proximity Read ↗

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.Semantic proximity Read ↗

Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.Semantic proximity Read ↗

HIV-1 genotypic and phenotypic resistance.Semantic proximity Read ↗

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.Semantic proximity Read ↗

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.Semantic proximity Read ↗

Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.Semantic proximity Read ↗

A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.Semantic proximity Read ↗

Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.